Your research can change the world
More on impact ›
Cancer Immunity and Immunotherapy welcomes submissions on tumor immunity in animal models and in human cancers and aims at driving the rapidly moving field of immunosurveillance, tumor escape, and immunotherapy by hosting primary research, discussions, reviews, conflicting positions, and novel hypotheses.
Dramatic progresses have been made in the field of cancer immunity and immunotherapy during the preceding 15 years.
The clinical impact associated with the tumor immune infiltrate, the impressive clinical activities of monoclonal antibodies modulating the immune microenvironment or directed to tumor cells, the successes of engineered T cells therapies and the development of cancer vaccines against mutated tumor antigens demonstrate that the immune system can be a powerful ally against cancer.
The section’s ambitions are to drive the rapidly moving field of immunosurveillance, tumor escape and immunotherapy by hosting primary research, discussions, reviews, conflicting positions and novel hypotheses.
Indexed in: PubMed, MEDLINE, PubMed Central (PMC), Scopus, Web of Science Science Citation Index Expanded (SCIE), Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Embase, Semantic Scholar, Ulrich's Periodicals Directory, CLOCKSS, EBSCO, OpenAIRE, Zetoc
PMCID: all published articles receive a PMCID
Cancer Immunity and Immunotherapy welcomes submissions of the following article types: Case Report, Classification, Clinical Trial, Correction, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Cancer Immunity and Immunotherapy, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01